Skip to main content
          Skip to FDA Search
          Skip to in this section menu
          Skip to footer links


U.S. flagAn official website of the United States government

					Here’s how you know
          			Dot gov**The .gov means it’s official.**Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you're on a federal government site.
							      SSL**The site is secure.** The **https://** ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely. 
			U.S. Food and Drug Administration
				
        Search
            Menu
							
						Search FDA
									
									Submit search 
		Featured
							Contact FDA
	                FDA Guidance Documents
	                Recalls, Market Withdrawals and Safety Alerts
	                Press Announcements
	                Warning Letters
	                Advisory Committees
	                En Español

					Products
            Food
							Drugs
							Medical Devices
							Radiation-Emitting Products
							Vaccines, Blood, and Biologics
							Animal and Veterinary
							Cosmetics
							Tobacco ProductsTopics
            About FDA
							Combination Products
							Regulatory Information
							Safety
							Emergency Preparedness
							International Programs
							News and Events
							Training and Continuing Education
							Inspections and Compliance
							Science and ResearchInformation For
            Consumers
	            Patients
	            Industry
	            Health Professionals
	            Federal, State and Local Officials 
 In this section:

                Guidances | Drugs

Guidances | Drugs

                        Product-Specific Guidances for Generic Drug Development
          Guidance Snapshot Pilot Home
          Drugs
          Guidance, Compliance, & Regulatory Information
          Guidances | Drugs
          Product-Specific Guidances for Generic Drug DevelopmentGuidances | Drugs Product-Specific Guidances for Generic Drug Development
  
  	
    Share
    Post
    Linkedin

    Email
    Print**Search Product-Specific Guidances for Generic Drug Development**

OGD_PSG Snapshot
FDA Product Specific Guidance Snapshot (PDF - 150 KB)

To further facilitate generic drug product availability and to assist the generic pharmaceutical industry with identifying the most appropriate methodology for developing drugs and generating evidence needed to support ANDA approval, FDA publishes product-specific guidances describing the agency’s current thinking and expectations on how to develop generic drug products therapeutically equivalent to specific reference listed drugs.

Increased transparency on product-specific guidances gives applicants seeking to develop generic drugs a better opportunity to efficiently allocate resources. The agency aims to ensure that policies and regulations – and scientific standards – keep pace with the science of equivalence. Improving patient access to high quality and affordable medicines supports FDA’s mission to advance the public health.

The agency routinely posts and revises product-specific guidances. FDA always seeks feedback and considers all comments to the docket before it begins work on the final versions of product-specific guidances. The FDA posts plans for issuing new or revised product-specific guidances on the Upcoming Product-Specific Guidances for Generic Drug Product Developmentweb page.

**The Product-Specific Guidances database features**:

Text search of PSGs by active ingredient or by the Reference Listed Drug (RLD) or Reference Standard (RS) application number
	Filtered search results using a text search box
	Option to export search results in Excel, CSV, or PDF format
	Paginated search results, allowing for faster searchingNew in Generic Drug User Fee Amendments (GDUFA) III

When a new or revised PSG is published and an applicant or prospective applicant has already commenced an in vivo bioequivalence study (i.e., the study protocol has been signed by the study sponsor and/or the contract research organization), the applicant or prospective applicant may request a PSG Teleconference to obtain agency feedback on the potential impact of the new or revised PSG on its development program. Pre-submission or post-submission PSG meetings may be requested following feedback received at the PSG teleconference. Refer to the GDUFA III Enhancements to the Pre-ANDA Program web page for additional details.

Resources

GDUFA III Enhancements for the Pre-ANDA Program
	FDA Product Specific Guidance Snapshot (PDF - 150 KB)
	FDA Product-Specific Guidances: Lighting the Development Pathway for Generic Drugs (pre-recorded webinar)
	How to Submit Comments on a Product-Specific Guidance
	Upcoming Product-Specific Guidances for Generic Drug Product Development
	Drug-Related General Guidances
	Bioequivalence Recommendations for Specific Products Final Guidance (June 2010) (PDF - 80 KB)
	Dissolution Methods Database
	Withdrawn CDER Product Specific Guidances (PDF - 90 KB)

                                                                                  Content current as of:
      11/21/2022Guidances | Drugs

          
                        Product-Specific Guidances for Generic Drug Development
          Guidance Snapshot Pilot
 
 Footer Links
    FDA Archive
          About FDA
          Accessibility
      Visitor Information
          Website Policies / Privacy
          No FEAR Act
          Vulnerability Disclosure Policy
      FOIA
          HHS.gov
          USA.gov
    Contact FDA
      Follow FDA on Facebook
      Follow FDA on X
      Follow FDA on Instagram
      Follow FDA on LinkedIn
      View FDA videos on YouTube
      Subscribe to FDA RSS feeds
    FDA Homepage
    Contact Number
      1-888-INFO-FDA (1-888-463-6332) Back toTop